Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00690313 |
Recruitment Status
: Unknown
Verified May 2008 by Illinois Retina Associates.
Recruitment status was: Not yet recruiting
First Posted
: June 4, 2008
Last Update Posted
: June 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.
In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intravitreal Injection Patients | Drug: Vigamox | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection |
Study Start Date : | July 2008 |
Estimated Primary Completion Date : | June 2009 |
Estimated Study Completion Date : | September 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Arm 1
Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
|
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
|
Active Comparator: Arm 2
Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
|
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
|
- Timed study [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient who need intravitreal injections patients who are willing to participate in the study
Exclusion Criteria:
- Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00690313
Contact: Kourous A Rezaei, MD | 708-596-8710 | karezaei@yahoo.com | |
Contact: David J Baczewski | 708-915-6808 | davidb@illinoisretina.com |
United States, Illinois | |
Illinois Retina Associates | Not yet recruiting |
Harvey, Illinois, United States, 60426 | |
Contact: David J Baczewski 708-915-6808 davidb@illinoisretina.com | |
Principal Investigator: Kourous A Rezaei, MD |
Principal Investigator: | Kourous A Rezaei, MD | Illinois Retina Associates SC |
Responsible Party: | Kourous Rezaei MD, Illinois Retina Associates SC |
ClinicalTrials.gov Identifier: | NCT00690313 History of Changes |
Other Study ID Numbers: |
Vig508 |
First Posted: | June 4, 2008 Key Record Dates |
Last Update Posted: | June 4, 2008 |
Last Verified: | May 2008 |
Keywords provided by Illinois Retina Associates:
Vigamox, topical antibiotics, Intravitreal injections, macular degeneration, endophthalmitis |
Additional relevant MeSH terms:
Ophthalmic Solutions Tetrahydrozoline Norgestimate, ethinyl estradiol drug combination Moxifloxacin Fluoroquinolones Pharmaceutical Solutions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Nasal Decongestants Vasoconstrictor Agents Respiratory System Agents |
Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Nucleic Acid Synthesis Inhibitors |